Sales: $121 million. Net income: $16 million.
Key Personnel: Albert Hummel, president, chief executive officer, director; Steve Carlson, president, chief executive officer, director; David Goldstein, executive vice president, global sales and field marketing; Laura Hunter, general counsel, secretary, vice president; Judith Hattendorf, senior vice president of product development.
Major Products: Nu-Derm, Clenziderm, Elastiderm, Obagi-C Rx, Rosaclear, Elastilash, Professional-C and ReGenica.
New Products: ReGenica Facial Rejuvenation Complex, Obagi Hydrate
Comments: With sales up 5.8% from last year, Obagi continues its impressive growth by focusing on expanding existing accounts while launching new products. One of its newer products, ReGenica Facial Rejuvenation Complex, was launched at the beginning of 2013 in partnership with Suneva Medical, Inc., a rapidly growing aesthetics company.
“We believe this relationship will accelerate our penetration in the marketplace and bring ReGenica Facial Rejuvenation Complex to more physicians in need of a cutting edge post-procedure solution and are excited to have a company as successful as Obagi as our partner,” said Nicholas Teti, chairman and chief executive officer of Suneva Medical.
The new technologically advanced product supports the rapid improvement in the appearance of post-laser skin by promoting the growth of new stem cells. Its Multipotent CCM (Cell Conditioned Media) Complex, developed by Dr. Gail Naughton, is composed of active growth factors and proteins that are not found in any other skin care product.
“The addition of the ReGenica line solidifies already existing evidence that Obagi is dedicated to delivering the efficacious, innovative products to patients seeking real solutions,” said Al Hummel, Obagi’s president and CEO. ‘The Facial Rejuvenation Complex addresses the need for the post-procedure skin care treatments that are not only gentle and safe for compromised skin, but also accelerate the visible improvement in the appearance of side effects associated with procedures.”
Its other new product, Obagi Hydrate, is already making an impressive impact in sales. Offered as both a vital component in the established Nu-Derm System and as a stand-alone product, Obagi Hydrate is credited with driving an increase in Nu-Derm sales and re-introduction of product sales in Texas. Obagi Hydrate, unlike other moisturizers, features an innovative technology called Hydromanil that captures water and assimilates it into the skin to help reduce water loss on the skin’s surface for a greater period of time.
Clinical trials have shown a 51% improvement in moisture loss after eight hours and a 92% improvement in the skin’s moisture retention within two hours.